№ files_lp_4_process_3_058600
File format: docx Character count: 6337 File size: 25 KB
Appeal letter urging immediate delivery of 1.4 million second doses of the Oxford-AstraZeneca vaccine to Nepal and broader international action to address critical shortages, document public health risks, and support equitable vaccine access.
Year: 2021
Region / city: Nepal
Topic: Public health / Covid-19 vaccination
Document type: Urgent action / appeal letter
Organization: Amnesty International
Author: Not specified
Target audience: International community, governments with vaccine surplus
Action deadline: 17 August 2021
Vaccine involved: Oxford-AstraZeneca
Population affected: Over 1.4 million high-risk individuals
First dose period: 7–15 March 2021
Required second dose period: 27 June–5 July 2021
Vaccination coverage at time of report: 2.4% fully vaccinated
Urgent needs: Immediate vaccine delivery, international support, TRIPS waiver advocacy
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Heber J. Grant Journal Entry on Oliver Cowdery (March–July 1881)
Year: 1881
Date range mentioned: March–July 1881
Topic: Oliver Cowdery
Document type: Journal entry excerpt
Collection: D. Michael Quinn Papers—Addition—Uncat WA MS 244
Accession: 19990209-c
Box: 1
File type: Card file
Author: Heber J. Grant
Person mentioned: Lysander Gee
Note: Person mentioned Oliver Cowdery
Religious context: Church of Jesus Christ of Latter-day Saints history
Repository collection note: D. Michael Quinn Papers
Protocol for the Adjustment of Insulin Doses in Diabetes
Document title: Protocol for the adjustment of insulin doses in diabetes
Organisation: Aneurin Bevan University Health Board
Service area: Adult Diabetes Service
Type of document: Clinical protocol
Target population: Adults with diabetes
Clinical setting: Acute and community settings
Intended users: Diabetes dietitians within the multidisciplinary team
Author: Elaine Hibbert-Jones
Contributors: Francesca Annan; Dorothy Debrah; Neera Agarwal; Kathryn John
Responsible committee: Medicines Management
Geographical scope: Wales
Insulin preparations: Aneurin Bevan Drug Formulary
Exclusions: Inpatients; pregnancy; paediatrics; insulin pump therapy without additional training
Date issued: May 2018
Review date: May 2021
Key topics: Insulin dose adjustment; hypoglycaemia; hyperglycaemia; blood glucose monitoring; basal and bolus insulin; injection technique
BECLOMETASONE with FORMOTEROL and GLYCOPYRRONIUM Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses, TRIMBOW®, Chiesi Australia Pty Ltd
Year: 2020
Region / city: Australia
Topic: Medical Submission for Pharmaceutical Product
Document Type: Submission
Organization / Institution: Chiesi Australia Pty Ltd
Author: Chiesi Australia Pty Ltd
Target Audience: Medical professionals, regulatory authorities
Period of validity: Not specified
Approval Date: June 24, 2020
Date of changes: Not specified
ESTRADIOL Transdermal gel (pump pack) 750 microgram (as hemihydrate) per 1.25 g dose, 64 doses, Estrogel®
Year: 2019
Region / City: Australia
Topic: Hormone Replacement Therapy (HRT)
Document Type: Regulatory Submission
Organization / Institution: Besins Healthcare Australia Pty Ltd
Author: Not specified
Target Audience: Health professionals and regulatory authorities
Period of Effectiveness: Not specified
Approval Date: 8 May 2019
Modification Date: Not specified
Registration Status: TGA Registered
Indications: Estrogen deficiency, prevention of osteoporosis, menstrual irregularities, hormone replacement therapy
Purpose: Request for listing of medications in General Schedule
Product Names: Estrogel®, Prometrium®, Estrogel Pro
Safety Data: Includes safety outcomes such as breast pain, tenderness, breakthrough bleeding, and breast cancer risk
Comparator Products: Sandrena®, MPA (medroxyprogesterone acetate)
Clinical Claims: Efficacy and safety comparison of Estrogel and MP to Sandrena and MPA
Source: Tables 1.2, pp23-24
Supplemental Tables of Estimated Chemical Risks and Relative Risk Ratios Based on MRL-Derived Benchmark Doses
Year: 2026
Region / City: Not specified
Subject: Chemical risk assessment, toxicology
Document Type: Supplemental tables
Institution / Agency: Not specified
Author: Not specified
Exposure Routes: Oral, Inhalation
Exposure Duration: Acute, Intermediate, Chronic
Data Type: Quantal, Continuous, Not applicable
Chemicals Included: Chromium (VI), 1,1,2,2-Tetrachloroethane, 1,3-Dichloropropene, Cresols, Ethylene Glycol, Tris(2-Chloroethyl) Phosphate, Tributyl Phosphate, Tris(2-Butoxyethyl) Phosphate, Tris(1,3-Dichloro-2-Propyl) Phosphate, Monomethylarsonic Acid, Dimethylarsinic Acid, Acrylamide, Toxaphene, Uranium, 2-Methylnaphthalene, Barium Salts, Boron Compounds, Cadmium, Vanadium Compounds, Benzene, 1,3 Butadiene, Polybrominated Diphenyl Ethers, Sulfur Mustard, Ethylbenzene, Toluene, Xylenes
MRL Values: Listed per chemical in mg/kg/day or mg/m³ or ppm
Risk Levels: K=1, Upper Bound Risk, Relative Risk Ratios (RR) at 2x and 5x MRL
Benchmark Dose Type: BMD, BMDL, BMCL, LOAEL
Prescribing Stimulant Medicines: Approved Conditions, Specialists, Age Criteria and Maximum Doses in Western Australia
Jurisdiction: Western Australia, Australia
Responsible authority: Department of Health
Subject: Prescribing of stimulant medicines
Document type: Prescribing guidance / regulatory information
Target users: Medical practitioners authorised to prescribe stimulant medicines
Approved conditions: ADHD; Acquired brain injury; Depression; Narcolepsy; Binge eating disorder
Approved specialists: Paediatrician; Neurologist; Paediatric neurologist; Psychiatrist; Child and adolescent psychiatrist; Rehabilitation physician; Paediatric rehabilitation physician; Respiratory and sleep physician; Thoracic medicine physician
Patient eligibility: Patients within specified approved age criteria depending on prescriber specialisation
Minimum patient age: 4 years (for child-specialist prescribers)
Maximum stimulant doses: Dexamfetamine up to 60 mg/day; Lisdexamfetamine up to 70 mg/day; Methylphenidate up to 120 mg/day; combination doses calculated as dexamfetamine equivalents
Prescription setting: Clinical treatment of approved conditions
Regulatory requirement: Notification to the Department of Health when commencing stimulant treatment or when specified patient or prescriber details change
Co-prescriber rules: Co-prescribers must be medical practitioners practising in Western Australia and recorded in the notification
Review requirement: Annual patient review by the primary stimulant prescriber
Contact service: Schedule 8 Medicines Prescriber Information Service
Telehealth provision: Interstate practitioners may prescribe via telehealth for Western Australian residents for prescriptions issued on or after 13 December 2023
Topics: Oxford-AstraZeneca March–July Doses